Kirn David 4
4 · 4D Molecular Therapeutics, Inc. · Filed Feb 23, 2023
Insider Transaction Report
Form 4
Kirn David
DirectorChief Executive Officer
Transactions
- Sale
Common Stock
2023-02-21$20.93/sh−17,090$357,718→ 1,876,509 total - Sale
Common Stock
2023-02-21$21.49/sh−907$19,491→ 1,875,602 total - Sale
Common Stock
2023-02-22$20.22/sh−16,449$332,665→ 1,859,153 total
Footnotes (4)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The transaction was executed in multiple trades in prices ranging from $20.35 to $21.305, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]The transaction was executed in multiple trades in prices ranging from $21.40 to $21.60, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]The transaction was executed in multiple trades in prices ranging from $19.96 to $20.71, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.